Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Evaluation of sNfL as a biomarker for paclitaxel-induced peripheral neurotoxicity through an integrated PKPD model
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.ORCID iD: 0000-0002-9282-9136
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.ORCID iD: 0000-0002-3701-3847
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.ORCID iD: 0000-0002-8702-6654
Show others and affiliations
2026 (English)In: Pharmaceutical research, ISSN 0724-8741, E-ISSN 1573-904X, Vol. 43, no 4, p. 1071-1088Article in journal (Refereed) Published
Abstract [en]

Background

Serum neurofilament light chain (sNfL), a biomarker of axonal damage, has shown promise in clinical studies for monitoring paclitaxel-induced peripheral neurotoxicity (PIPN). The latter involves pathological changes in PIPN sites such as the dorsal root ganglia, peripheral nerves, and brain. However, the mechanistic link between paclitaxel and NfL concentrations in these tissues remains poorly understood, necessitating preclinical investigation.

Methods

We developed a semi-mechanistic pharmacokinetic-pharmacodynamic model to characterize: (i) total and unbound paclitaxel concentrations in plasma, as well as in extracellular and intracellular compartments of PIPN sites; (ii) paclitaxel–tubulin complex formation; and (iii) NfL kinetics. The model was built using de novo-generated and previously reported data from rodents.

Results

Plasma pharmacokinetics of paclitaxel was captured using a two-compartment model, including Cremophor EL trapping and nonlinear tissue distribution. Paclitaxel pharmacokinetics in PIPN sites incorporated paclitaxel transport across the blood-to-PIPN sites barriers and paclitaxel–tubulin binding, described by capacity-limited kinetics with increased tubulin binding upon repeated plasma exposure. NfL kinetics in serum and cerebrospinal fluid were described using turnover models, with NfL leakage driven by paclitaxel–tubulin complex formation in PIPN sites. The model robustly predicted paclitaxel exposure across multiple doses and studies. While NfL predictions aligned with single-dose data, the model slightly underpredicted sNfL levels in an external validation dataset after repeated dosing of paclitaxel at 15 mg/kg, suggesting additional mechanisms may be involved.

Conclusions

Overall, the model successfully described the relationship between paclitaxel exposure and sNfL kinetics, offering a model-based framework for translational studies.

Place, publisher, year, edition, pages
Springer, 2026. Vol. 43, no 4, p. 1071-1088
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-565552DOI: 10.1007/s11095-026-04053-zISI: 001714659900001PubMedID: 41826588Scopus ID: 2-s2.0-105033760482OAI: oai:DiVA.org:uu-565552DiVA, id: diva2:1991358
Available from: 2025-08-22 Created: 2025-08-22 Last updated: 2026-09-20Bibliographically approved
In thesis
1. Mechanism-based pharmacometric models to improve the development and use of anticancer therapies
Open this publication in new window or tab >>Mechanism-based pharmacometric models to improve the development and use of anticancer therapies
2025 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Oncology drug development remains one of the most challenging domains in pharmaceutical research, marked by high attrition rates, suboptimal dose selection, and limited translatability of preclinical findings, particularly with the emerging therapeutic modalities. Model-informed drug development (MIDD) provides a quantitative paradigm for integrating data across the preclinical-to-clinical continuum, thereby enabling evidence-based decision-making. Within this paradigm, mechanism-based pharmacometric models facilitate a structured MIDD approach by quantitatively capturing the interplay between drug exposure, pharmacological response, disease progression, and adverse events. This thesis leverages such models to address key questions in oncology drug development, informing dose optimisation, biomarker qualification, and therapeutic strategy. 

Therapeutic cancer vaccines stimulate the immune system to recognise and eradicate cancer cells. The adaptable drug affinity conjugate (ADAC) platform, in preclinical development, employs a bispecific antibody engineered to bind a pTag–peptide sequence. A novel multiscale semi-mechanistic pharmacokinetic-pharmacodynamic (PKPD) modelling framework was developed to characterise ADAC-induced immune responses and tumour dynamics in inflamed and non-inflamed murine tumour models. Model-based simulations demonstrated that higher pTag binding affinity prolonged peptide residence time and enhanced antitumor activity. UV1, a telomerase-based vaccine, was evaluated in Phase I trials. A mechanistic modelling framework, integrating tumour size, immune response, and survival data, suggested extending maintenance dosing for more sustained tumour shrinkage. 

Ibrutinib, a Bruton’s tyrosine kinase inhibitor for chronic lymphocytic leukaemia, is frequently associated with hypertension, often necessitating dose modifications in clinical practice. A novel semi-mechanistic PKPD modelling framework was constructed to delineate the relationships among plasma exposure, leukocyte and lymphocyte dynamics, lymph node and spleen size, and blood pressure. Model-based dose reduction simulations suggested that therapeutic efficacy could be maintained while reducing hypertension risk. 

Paclitaxel-induced peripheral neurotoxicity (PIPN) is a common dose-limiting toxicity, with serum neurofilament light chain (sNfL) emerging as a promising neurotoxicity biomarker. A translational integrated plasma-PIPN sites PK model, developed using preclinical data and scaled to humans, was linked to a novel PKPD model describing the relationship between paclitaxel exposure, sNfL, and Total Neuropathy Score–clinical version in breast cancer patients. Model-based landmark analysis highlighted sNfL as a potential predictive biomarker for PIPN severity. 

In summary, this thesis demonstrates the utility of mechanism-based pharmacometric modelling in integrating diverse data types into an informative and predictive framework. Through applications spanning diverse therapeutic modalities, this work advances model-based strategies to improve decision-making across the drug development lifecycle. 

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2025. p. 90
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 384
Keywords
pharmacometrics, oncology, model-informed drug development, dose optimisation, pharmacokinetics, pharmacodynamics, biomarkers.
National Category
Pharmaceutical Sciences
Research subject
Pharmaceutical Science
Identifiers
urn:nbn:se:uu:diva-565557 (URN)978-91-513-2574-3 (ISBN)
Public defence
2025-10-16, A1:107a, BMC, Husargatan 3, Uppsala, 09:15 (English)
Opponent
Supervisors
Funder
Swedish Cancer Society, CAN 2017/626, 20 1226 PjF, and 23 2921 Pj
Available from: 2025-09-25 Created: 2025-08-28 Last updated: 2025-09-25
2. Pharmacokinetic Mechanisms in the Development and Prevention of Chemotherapy-Induced Peripheral Neuropathy
Open this publication in new window or tab >>Pharmacokinetic Mechanisms in the Development and Prevention of Chemotherapy-Induced Peripheral Neuropathy
2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting adverse effect of anticancer microtubule-targeting agents (MTAs). However, the pharmacologically active unbound exposure of MTAs at CIPN-relevant sites, including peripheral and central nervous system tissues and skeletal muscle, and its relationship to neurotoxicity and biomarkers remain incompletely characterized. The overall aim of this thesis was to investigate MTAs distribution and intra- and extracellular exposure at CIPN-relevant sites using preclinical models and integrating these findings with pharmacokinetic-pharmacodynamic (PKPD) modelling and biomarker evaluation to improve understanding and monitoring of CIPN in patients.

Particular emphasis was placed on paclitaxel-induced peripheral neuropathy (PIPN), with focus on drug formulation, translational pharmacokinetics, and serum neurofilament light chain (sNfL) as a biomarker of axonal injury. Albumin-bound and micellar paclitaxel formulations showed greater unbound distribution across endothelial barriers at CIPN-relevant sites, expressed as the unbound tissue-to-plasma concentration ratio (Kp,uu,tissue), than paclitaxel formulated with Cremophor EL. Results provide a plausible mechanistic explanation for the higher incidence of CIPN with non-Cremophor EL formulations. Based on PIPN site pharmacokinetic data, a semi-mechanistic PKPD model was developed linking sNfL kinetics to intracellular paclitaxel-tubulin binding in dorsal root ganglia, peripheral nerves, and brain. The framework was translated to humans, where sNfL dynamics were related to the Total Neuropathy Score-clinical version in breast cancer patients. sNfL showed moderate predictive performance for CIPN, highlighting the multifactorial nature of PIPN.

The thesis was subsequently extended to cabazitaxel, docetaxel, vinorelbine, and eribulin to investigate whether differences in CIPN prevalence could be related to MTA distribution at CIPN-relevant sites. Despite differences in the time required to reach steady-state, governed by tubulin abundance and transporter-mediated distribution across endothelial and parenchymal barriers, all MTAs showed a similar distribution pattern, with greater distribution into PNS than CNS tissues. Thus, dissimilarities in clinical unbound plasma exposure, rather than in tissue distribution patterns, may be important determinants of intracellular exposure and neurotoxicity.

Together, the translational framework developed in this thesis links drug exposure, intracellular target engagement, and sNfL dynamics from preclinical to clinical settings. It provides a rationale for PK-informed CIPN assessment and for the development of novel MTAs with reduced neurotoxicity.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2026. p. 72
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 410
Keywords
chemotherapy-induced peripheral neuropathy, blood-dorsal root ganglion barrier, blood-nerve barrier, blood-brain barrier, taxanes, Vinca alkaloids, drug distribution
National Category
Pharmaceutical Sciences
Research subject
Pharmaceutical Science
Identifiers
urn:nbn:se:uu:diva-599159 (URN)978-91-513-2960-4 (ISBN)
Public defence
2026-11-06, Room IV, Biskopsgatan 3, Uppsala, 09:15 (English)
Opponent
Supervisors
Available from: 2026-10-14 Created: 2026-09-20 Last updated: 2026-10-14

Open Access in DiVA

fulltext(2633 kB)104 downloads
File information
File name FULLTEXT01.pdfFile size 2633 kBChecksum SHA-512
104cd91c9c6f8d2ef461e84ba519554551888564df488d761f4b7d3a060b75da1ebeac06d6cfac85c60f8a8123c98dcf46e717d8e48590c1d30dcf081f57a2c9
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Ibrahim, Eman I.K.Girdenytė, MildaHu, YangLoryan, IrenaFriberg, Lena E.

Search in DiVA

By author/editor
Ibrahim, Eman I.K.Girdenytė, MildaHu, YangLoryan, IrenaFriberg, Lena E.
By organisation
Department of Pharmacy
In the same journal
Pharmaceutical research
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 104 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 131 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf